{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:37:54Z","timestamp":1787593074651,"version":"build-2736575974"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s40266-024-01138-5","type":"journal-article","created":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T12:02:22Z","timestamp":1723636942000},"page":"725-740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Direct Oral Anticoagulants  in Older and Frail Patients with Atrial Fibrillation: A Decade of Experience"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5157-590X","authenticated-orcid":false,"given":"Jocelyn R.","family":"Spruit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim A. C.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E. W.","family":"Hemels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Pisters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris R.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9 W. M. M.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,14]]},"reference":[{"issue":"10","key":"1138_CR1","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"365","author":"MR Patel","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883\u201391.","journal-title":"N Engl J Med"},{"issue":"11","key":"1138_CR2","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"12","key":"1138_CR3","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139\u201351.","journal-title":"N Engl J Med"},{"issue":"22","key":"1138_CR4","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093\u2013104.","journal-title":"N Engl J Med"},{"issue":"02","key":"1138_CR5","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1055\/s-0037-1613679","volume":"01","author":"V Bhagirath","year":"2017","unstructured":"Bhagirath V, Eikelboom J, Hirsh J, Coppens M, Ginsberg J, Vanassche T, et al. Apixaban-calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial. TH Open. 2017;01(02):e139\u201345.","journal-title":"TH Open."},{"issue":"9984","key":"1138_CR6","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","volume":"385","author":"CT Ruff","year":"2015","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288\u201395.","journal-title":"Lancet"},{"issue":"1","key":"1138_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11239-020-02077-9","volume":"50","author":"L Zhang","year":"2020","unstructured":"Zhang L, Yan X, Fox KAA, Willmann S, Nandy P, Berkowitz SD, et al. Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis. 2020;50(1):20\u20139.","journal-title":"J Thromb Thrombolysis"},{"issue":"4","key":"1138_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","volume":"63","author":"PA Reilly","year":"2014","unstructured":"Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol. 2014;63(4):321\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1138_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.2147\/VHRM.S187656","volume":"15","author":"J Seelig","year":"2019","unstructured":"Seelig J, Pisters R, Hemels M, Huisman MV, ten Cate H, Alings M. When to withhold oral anticoagulation in atrial fibrillation\u2014an overview of frequent clinical discussion topics. Vasc Health Risk Manag. 2019;15:399\u2013408.","journal-title":"Vasc Health Risk Manag."},{"issue":"4","key":"1138_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ahj.2013.12.014","volume":"167","author":"EC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien EC, Holmes DN, Ansell JE, Allen LA, Hylek E, Kowey PR, et al. Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Am Heart J. 2014;167(4):601-609.e1.","journal-title":"Am Heart J"},{"issue":"2","key":"1138_CR11","doi-asserted-by":"publisher","first-page":"102","DOI":"10.15420\/AER.2016.20.3","volume":"5","author":"M Alings","year":"2016","unstructured":"Alings M. Individualising anticoagulant therapy in atrial fibrillation patients. Arrhythm Electrophysiol Rev. 2016;5(2):102.","journal-title":"Arrhythm Electrophysiol Rev."},{"issue":"5","key":"1138_CR12","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"G Hindricks","year":"2021","unstructured":"Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstr\u00f6m-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373\u2013498.","journal-title":"Eur Heart J"},{"issue":"2","key":"1138_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jjcc.2018.01.015","volume":"72","author":"IS Kim","year":"2018","unstructured":"Kim IS, Kim HJ, Kim TH, Uhm JS, Joung B, Lee MH, et al. Non-vitamin K antagonist oral anticoagulants have better efficacy and equivalent safety compared to warfarin in elderly patients with atrial fibrillation: a systematic review and meta-analysis. J Cardiol. 2018;72(2):105\u201312.","journal-title":"J Cardiol"},{"issue":"22","key":"1138_CR14","doi-asserted-by":"publisher","first-page":"5268","DOI":"10.3390\/jcm10225268","volume":"10","author":"C Bonanad","year":"2021","unstructured":"Bonanad C, Garc\u00eda-Blas S, Torres Llergo J, Fern\u00e1ndez-Olmo R, D\u00edez-Villanueva P, Ariza-Sol\u00e9 A, et al. Direct oral anticoagulants versus warfarin in octogenarians with nonvalvular atrial fibrillation: a systematic review and meta-analysis. J Clin Med. 2021;10(22):5268.","journal-title":"J Clin Med"},{"key":"1138_CR15","doi-asserted-by":"crossref","unstructured":"Lee KH, Chen YF, Yeh WY, Yeh JT, Yang TH, Chou CY, et al. Optimal stroke preventive strategy for patients aged 80 years or older with atrial fibrillation: a systematic review with traditional and network meta-analysis. Age Ageing. 2022;51(12), afac292.","DOI":"10.1093\/ageing\/afac292"},{"issue":"FI1","key":"1138_CR16","doi-asserted-by":"publisher","first-page":"f20","DOI":"10.1093\/ehjcvp\/pvz073","volume":"7","author":"A Silverio","year":"2021","unstructured":"Silverio A, Di Maio M, Prota C, De Angelis E, Radano I, Citro R, et al. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients. Eur Heart J Cardiovasc Pharmacother. 2021;7(FI1):f20\u20139.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"1138_CR17","doi-asserted-by":"crossref","unstructured":"Shen NN, Wu Y, Wang N, Kong LC, Zhang C, Wang JL, et al. Direct oral anticoagulants vs. vitamin-K antagonists in the elderly with atrial fibrillation: a systematic review comparing benefits and harms between observational studies and randomized controlled trials. Front Cardiovasc Med. 2020;7, 132.","DOI":"10.3389\/fcvm.2020.00132"},{"issue":"4","key":"1138_CR18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/jcm8040554","volume":"8","author":"A Mitchell","year":"2019","unstructured":"Mitchell A, Watson MC, Welsh T, McGrogan A. Effectiveness and safety of direct oral anticoagulants versus vitamin K antagonists for people aged 75 years and over with atrial fibrillation: a systematic review and meta-analyses of observational studies. J Clin Med. 2019;8(4):554.","journal-title":"J Clin Med"},{"issue":"8","key":"1138_CR19","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1111\/jgs.15956","volume":"67","author":"S Deitelzweig","year":"2019","unstructured":"Deitelzweig S, Keshishian A, Li X, Kang A, Dhamane AD, Luo X, et al. Comparisons between oral anticoagulants among older nonvalvular atrial fibrillation patients. J Am Geriatr Soc. 2019;67(8):1662\u201371.","journal-title":"J Am Geriatr Soc"},{"key":"1138_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejim.2018.04.023","volume":"56","author":"U Junius-Walker","year":"2018","unstructured":"Junius-Walker U, Onder G, Soleymani D, Wiese B, Albaina O, Bernabei R, et al. The essence of frailty: a systematic review and qualitative synthesis on frailty concepts and definitions. Eur J Intern Med. 2018;56:3\u201310.","journal-title":"Eur J Intern Med"},{"issue":"12","key":"1138_CR21","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-032488","volume":"9","author":"LPT Joosten","year":"2019","unstructured":"Joosten LPT, van Doorn S, Hoes AW, Nierman MC, Wiersma NM, Koek HL, et al. Safety of switching from vitamin K antagonist to non-vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open. 2019;9(12): e032488.","journal-title":"BMJ Open"},{"key":"1138_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.ahj.2018.09.017","volume":"208","author":"KP Alexander","year":"2019","unstructured":"Alexander KP, Brouwer MA, Mulder H, Vinereanu D, Lopes RD, Proietti M, et al. Outcomes of apixaban versus warfarin in patients with atrial fibrillation and multi-morbidity: Insights from the ARISTOTLE trial. Am Heart J. 2019;208:123\u201331.","journal-title":"Am Heart J"},{"key":"1138_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2868","author":"J Jaspers Focks","year":"2016","unstructured":"Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ [Internet]. 2016. https:\/\/doi.org\/10.1136\/bmj.i2868.","journal-title":"BMJ [Internet]."},{"key":"1138_CR24","doi-asserted-by":"crossref","unstructured":"Martinez BK, Sood NA, Bunz TJ, Coleman CI. Effectiveness and safety of apixaban, dabigatran, and rivaroxaban versus warfarin in frail patients with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7(8) e008643.","DOI":"10.1161\/JAHA.118.008643"},{"issue":"3","key":"1138_CR25","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/ehjcvp\/pvz061","volume":"6","author":"AM Nicolau","year":"2020","unstructured":"Nicolau AM, Corbalan R, Nicolau JC, Ruff CT, Zierhut W, Kerschnitzki M, et al. Efficacy and safety of edoxaban compared with warfarin according to the burden of diseases in patients with atrial fibrillation: insights from the ENGAGE AF-TIMI 48 trial. Eur Heart J Cardiovasc Pharmacother. 2020;6(3):167\u201375.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"issue":"4","key":"1138_CR26","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.115.018544","volume":"133","author":"JP Piccini","year":"2016","unstructured":"Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz SD, et al. Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. Circulation. 2016;133(4):352\u201360.","journal-title":"Circulation"},{"issue":"06","key":"1138_CR27","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1055\/s-0039-1683422","volume":"119","author":"C Hohmann","year":"2019","unstructured":"Hohmann C, Hohnloser SH, Jacob J, Walker J, Baldus S, Pfister R. Non-vitamin K oral anticoagulants in comparison to phenprocoumon in geriatric and non-geriatric patients with non-valvular atrial fibrillation. Thromb Haemost. 2019;119(06):971\u201380.","journal-title":"Thromb Haemost"},{"issue":"9","key":"1138_CR28","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.7326\/M20-7141","volume":"174","author":"DH Kim","year":"2021","unstructured":"Kim DH, Pawar A, Gagne JJ, Bessette LG, Lee H, Glynn RJ, et al. Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation. Ann Intern Med. 2021;174(9):1214\u201323.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1138_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1186\/s12916-020-01870-w","volume":"18","author":"C Wilkinson","year":"2020","unstructured":"Wilkinson C, Wu J, Searle SD, Todd O, Hall M, Kunadian V, et al. Clinical outcomes in patients with atrial fibrillation and frailty: insights from the ENGAGE AF-TIMI 48 trial. BMC Med. 2020;18(1):401.","journal-title":"BMC Med"},{"key":"1138_CR30","doi-asserted-by":"crossref","unstructured":"Zeng S, Zheng Y, Jiang J, Ma J, Zhu W, Cai X. Effectiveness and safety of DOACs vs. warfarin in patients with atrial fibrillation and frailty: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;9, 907197.","DOI":"10.3389\/fcvm.2022.907197"},{"key":"1138_CR31","doi-asserted-by":"crossref","unstructured":"Joosten LPT, van Doorn S, van de Ven PM, K\u00f6hlen BTG, Nierman MC, Koek HL, et al. Safety of switching from a vitamin K antagonist to a non-vitamin k antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial. Circulation. 2023,149(4), 279\u2013289.","DOI":"10.1161\/CIRCULATIONAHA.123.066485"},{"issue":"3","key":"1138_CR32","first-page":"269.e2","volume":"131","author":"MP Rao","year":"2018","unstructured":"Rao MP, Vinereanu D, Wojdyla DM, Alexander JH, Atar D, Hylek EM, et al. Clinical outcomes and history of fall in patients with atrial fibrillation treated with oral anticoagulation: insights from the ARISTOTLE trial. Am J Med [Internet]. 2018;131(3), 269\u2013275.e2.","journal-title":"Am J Med [Internet]."},{"issue":"11","key":"1138_CR33","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.jacc.2016.06.034","volume":"68","author":"J Steffel","year":"2016","unstructured":"Steffel J, Giugliano RP, Braunwald E, Murphy SA, Mercuri M, Choi Y, et al. Edoxaban versus warfarin in atrial fibrillation patients at risk of falling. J Am Coll Cardiol [Internet]. 2016;68(11):1169\u201378.","journal-title":"J Am Coll Cardiol [Internet]"},{"issue":"5","key":"1138_CR34","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","volume":"50","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg. 2016;50(5):e1-88.","journal-title":"Eur J Cardiothorac Surg"},{"issue":"16","key":"1138_CR35","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","volume":"39","author":"J Steffel","year":"2018","unstructured":"Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330\u201393.","journal-title":"Eur Heart J"},{"key":"1138_CR36","doi-asserted-by":"crossref","unstructured":"Gao X, Huang D, Hu Y, Chen Y, Zhang H, Liu F, et al. Direct oral anticoagulants vs. vitamin K antagonists in atrial fibrillation patients at risk of falling: a meta-analysis. Front Cardiovasc Med. 2022;9, 833329.","DOI":"10.3389\/fcvm.2022.833329"},{"key":"1138_CR37","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ahj.2021.12.017","volume":"247","author":"B Gencer","year":"2022","unstructured":"Gencer B, Eisen A, Berger D, Nordio F, Murphy SA, Grip LT, et al. Edoxaban versus warfarin in high-risk patients with atrial fibrillation: a comprehensive analysis of high-risk subgroups. Am Heart J. 2022;247:24\u201332.","journal-title":"Am Heart J"},{"key":"1138_CR38","first-page":"11","volume":"9","author":"M Grymonprez","year":"2020","unstructured":"Grymonprez M, Steurbaut S, De Backer TL, Petrovic M, Lahousse L. Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis. Front Pharmacol. 2020;9:11.","journal-title":"Front Pharmacol"},{"issue":"10","key":"1138_CR39","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, et al. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. EP Europace. 2021;23(10):1612\u201376.","journal-title":"EP Europace."},{"issue":"11","key":"1138_CR40","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.2215\/CJN.02400311","volume":"6","author":"RG Hart","year":"2011","unstructured":"Hart RG, Pearce LA, Asinger RW, Herzog CA. Warfarin in atrial fibrillation patients with moderate chronic kidney disease. Clin J Am Soc Nephrol. 2011;6(11):2599\u2013604.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"1138_CR41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.7326\/M19-0087","volume":"171","author":"JT Ha","year":"2019","unstructured":"Ha JT, Neuen BL, Cheng LP, Jun M, Toyama T, Gallagher MP, et al. Benefits and harms of oral anticoagulant therapy in chronic kidney disease. Ann Intern Med. 2019;171(3):181.","journal-title":"Ann Intern Med"},{"issue":"17","key":"1138_CR42","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1016\/j.jacc.2019.08.1031","volume":"74","author":"S Kumar","year":"2019","unstructured":"Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, et al. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation. J Am Coll Cardiol. 2019;74(17):2204\u201315.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1138_CR43","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1161\/CIRCRESAHA.116.306925","volume":"118","author":"NC Chan","year":"2016","unstructured":"Chan NC, Eikelboom JW, Weitz JI. Evolving treatments for arterial and venous thrombosis. Circ Res. 2016;118(9):1409\u201324.","journal-title":"Circ Res"},{"issue":"1","key":"1138_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/medicines10010013","volume":"10","author":"Y Wang","year":"2023","unstructured":"Wang Y, Li L, Wei Z, Lu S, Liu W, Zhang J, et al. Efficacy and safety of renal function on edoxaban versus warfarin for atrial fibrillation: a systematic review and meta-analysis. Medicines. 2023;10(1):13.","journal-title":"Medicines"},{"issue":"17","key":"1138_CR45","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.119.044059","volume":"141","author":"JW Stanifer","year":"2020","unstructured":"Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, et al. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(17):1384\u201392.","journal-title":"Circulation"},{"issue":"6","key":"1138_CR46","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1097\/FJC.0000000000000911","volume":"76","author":"Z Heleniak","year":"2020","unstructured":"Heleniak Z, Papuga-Szela E, Krzysztof P, Anetta U. Efficacy and safety of non-vitamin k antagonist oral anticoagulants in patients with atrial fibrillation and chronic kidney disease stage G4: a single-center experience. J Cardiovasc Pharmacol. 2020;76(6):671\u20137.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"23","key":"1138_CR47","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR, Gallup D, Dignacco P, Mussina K, et al. Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation. 2022;146(23):1735\u201345.","journal-title":"Circulation"},{"key":"1138_CR48","first-page":"9","volume":"10","author":"TM Rhee","year":"2022","unstructured":"Rhee TM, Lee SR, Choi EK, Oh S, Lip GYH. Efficacy and safety of oral anticoagulants for atrial fibrillation patients with chronic kidney disease: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;10:9.","journal-title":"Front Cardiovasc Med."},{"issue":"10","key":"1138_CR49","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1093\/eurheartj\/ehz385","volume":"41","author":"G Piazza","year":"2020","unstructured":"Piazza G, Hurwitz S, Galvin CE, Harrigan L, Baklla S, Hohlfelder B, et al. Alert-based computerized decision support for high-risk hospitalized patients with atrial fibrillation not prescribed anticoagulation: a randomized, controlled trial (AF-ALERT). Eur Heart J. 2020;41(10):1086\u201396.","journal-title":"Eur Heart J"},{"key":"1138_CR50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ijcard.2018.03.053","volume":"261","author":"M Proietti","year":"2018","unstructured":"Proietti M, Romiti GF, Romanazzi I, Farcomeni A, Staerk L, Nielsen PB, et al. Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2018;261:84\u201391.","journal-title":"Int J Cardiol"},{"issue":"14","key":"1138_CR51","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1056\/NEJMoa1814051","volume":"380","author":"SJ Connolly","year":"2019","unstructured":"Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH, et al. Full study report of andexanet alfa for bleeding associated with factor Xa inhibitors. N Engl J Med. 2019;380(14):1326\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"1138_CR52","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s40256-022-00530-z","volume":"22","author":"BH Suah","year":"2022","unstructured":"Suah BH, Lee ZY, Teo YH, Teo YN, Syn NLX, Soh RYH, et al. Comparison of the efficacy and safety of non-vitamin K antagonist oral anticoagulants with warfarin in atrial fibrillation patients with a history of bleeding: a systematic review and meta-analysis. Am J Cardiovasc Drugs [Internet]. 2022;22(5):511\u201321. https:\/\/doi.org\/10.1007\/s40256-022-00530-z.","journal-title":"Am J Cardiovasc Drugs [Internet]."},{"key":"1138_CR53","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.ahj.2016.01.005","volume":"175","author":"R De Caterina","year":"2016","unstructured":"De Caterina R, Andersson U, Alexander JH, Al-Khatib SM, Bahit MC, Goto S, et al. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation trial. Am Heart J. 2016;175:175\u201383.","journal-title":"Am Heart J"},{"issue":"9921","key":"1138_CR54","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","volume":"383","author":"CT Ruff","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955\u201362.","journal-title":"Lancet"},{"issue":"Supplement A","key":"1138_CR55","doi-asserted-by":"publisher","first-page":"A1","DOI":"10.1093\/eurheartj\/suab150","volume":"24","author":"RP Giugliano","year":"2022","unstructured":"Giugliano RP. Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation. Eur Heart J Suppl. 2022;24(Supplement A):A1-10.","journal-title":"Eur Heart J Suppl."},{"key":"1138_CR56","first-page":"9","volume":"27","author":"J Zhao","year":"2022","unstructured":"Zhao J, Wu X, Li S, Gu Q. Effectiveness and safety of oral anticoagulant therapy in patients with atrial fibrillation with prior gastrointestinal bleeding: a systematic review and meta-analysis. Front Cardiovasc Med. 2022;27:9.","journal-title":"Front Cardiovasc Med."},{"issue":"7","key":"1138_CR57","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00228-022-03300-7","volume":"78","author":"W Hu","year":"2022","unstructured":"Hu W, Cai H, Zhang J. Direct oral anticoagulants versus warfarin in nonvalvular atrial fibrillation patients with prior gastrointestinal bleeding: a network meta-analysis of real-world data. Eur J Clin Pharmacol. 2022;78(7):1057\u201367.","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"1138_CR58","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1007\/s11883-018-0733-y","volume":"20","author":"YG Li","year":"2018","unstructured":"Li YG, Lip GY. Anticoagulation resumption after intracerebral hemorrhage. Curr Atheroscler Rep. 2018;20(7):32.","journal-title":"Curr Atheroscler Rep"},{"key":"1138_CR59","doi-asserted-by":"crossref","unstructured":"Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, et al. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. J Am Heart Assoc. 2015;4(12).","DOI":"10.1161\/JAHA.115.002015"},{"key":"1138_CR60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ahj.2016.05.001","volume":"178","author":"S Vemulapalli","year":"2016","unstructured":"Vemulapalli S, Hellkamp AS, Jones WS, Piccini JP, Mahaffey KW, Becker RC, et al. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: results from the ROCKET AF trial. Am Heart J. 2016;178, 74\u201384.","journal-title":"Am Heart J"},{"issue":"3","key":"1138_CR61","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/HYPERTENSIONAHA.119.13138","volume":"74","author":"S Park","year":"2019","unstructured":"Park S, Bergmark BA, Shi M, Lanz HJ, Chung N, Ruff CT, et al. Edoxaban versus warfarin stratified by average blood pressure in 19 679 patients with atrial fibrillation and a history of hypertension in the ENGAGE AF-TIMI 48 trial. Hypertension. 2019;74(3):597\u2013605.","journal-title":"Hypertension"},{"issue":"8","key":"1138_CR62","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.amjcard.2015.07.032","volume":"116","author":"R Nagarakanti","year":"2015","unstructured":"Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, et al. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY trial). Am J Cardiol. 2015;116(8):1204\u20139.","journal-title":"Am J Cardiol"},{"issue":"3","key":"1138_CR63","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/00015385.2021.1882111","volume":"77","author":"RE Harskamp","year":"2022","unstructured":"Harskamp RE, Lucassen WAM, Lopes RD, Himmelreich JCL, Parati G, van Weert HCPM. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol. 2022;77(3):191\u20135.","journal-title":"Acta Cardiol"},{"key":"1138_CR64","doi-asserted-by":"crossref","unstructured":"de Vries TAC, Hirsh J, Chan NC. Letter by de Vries et al Regarding article \u201coff-label under- and overdosing of direct oral anticoagulants in patients with atrial fibrillation: a meta-analysis.\u201d Circ Cardiovasc Qual Outcomes. 2022;15(5).","DOI":"10.1161\/CIRCOUTCOMES.122.008982"},{"issue":"09","key":"1138_CR65","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1055\/s-0040-1713889","volume":"120","author":"TAC de Vries","year":"2020","unstructured":"de Vries TAC, Hirsh J, Xu K, Mallick I, Bhagirath VC, Eikelboom JW, et al. Apixaban for stroke prevention in atrial fibrillation: why are event rates higher in clinical practice than in randomized trials?\u2014a systematic review. Thromb Haemost. 2020;120(09):1323\u20139.","journal-title":"Thromb Haemost"},{"issue":"8","key":"1138_CR66","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.mayocp.2018.01.028","volume":"93","author":"JM Rivera-Caravaca","year":"2018","unstructured":"Rivera-Caravaca JM, Esteve-Pastor MA, Mar\u00edn F, Vald\u00e9s M, Vicente V, Rold\u00e1n V, et al. A propensity score matched comparison of clinical outcomes in atrial fibrillation patients taking vitamin K antagonists: comparing the \u201creal-world\u201d vs clinical trials. Mayo Clin Proc. 2018;93(8):1065\u201373.","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"1138_CR67","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1016\/j.jacc.2020.09.615","volume":"76","author":"VC Bhagirath","year":"2020","unstructured":"Bhagirath VC, Chan N, Hirsh J, Ginsberg J, de Vries TAC, Eikelboom J. Plasma apixaban levels in patients treated off label with the lower dose. J Am Coll Cardiol. 2020;76(24):2906\u20137.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"1138_CR68","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.28500","volume":"5","author":"S Akashi","year":"2022","unstructured":"Akashi S, Oguri M, Ikeno E, Manita M, Taura J, Watanabe S, et al. Outcomes and safety of very-low-dose edoxaban in frail patients with atrial fibrillation in the ELDERCARE-AF randomized clinical trial. JAMA Netw Open. 2022;5(8): e2228500.","journal-title":"JAMA Netw Open"},{"key":"1138_CR69","unstructured":"Jorgal. A, OCEANIC-AF data on file. November 2023. https:\/\/www.bayer.com\/media\/en-us\/oceanic-af-study-stopped-early-due-to-lack-of-efficacy\/"},{"issue":"2","key":"1138_CR70","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/jth.15577","volume":"20","author":"BA Yi","year":"2022","unstructured":"Yi BA, Freedholm D, Widener N, Wang X, Simard E, Cullen C, et al. Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa. J Thromb Haemost. 2022;20(2):307\u201315.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"1138_CR71","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1177\/2396987319863606","volume":"4","author":"N Ahmed","year":"2019","unstructured":"Ahmed N, Audebert H, Turc G, Cordonnier C, Christensen H, Sacco S, et al. Consensus statements and recommendations from the ESO-Karolinska stroke update conference, Stockholm 11\u201313 November 2018. Eur Stroke J [Internet]. 2019;4(4):307\u201317. https:\/\/doi.org\/10.1177\/2396987319863606.","journal-title":"Eur Stroke J [Internet]."},{"issue":"9689","key":"1138_CR72","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","volume":"374","author":"DR Holmes","year":"2009","unstructured":"Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534\u201342.","journal-title":"Lancet"},{"issue":"1","key":"1138_CR73","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jacc.2021.10.023","volume":"79","author":"P Osmancik","year":"2022","unstructured":"Osmancik P, Herman D, Neuzil P, Hala P, Taborsky M, Kala P, et al. 4-year outcomes after left atrial appendage closure versus nonwarfarin oral anticoagulation for atrial fibrillation. J Am Coll Cardiol. 2022;79(1):1\u201314.","journal-title":"J Am Coll Cardiol"},{"key":"1138_CR74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.carrev.2021.04.019","volume":"36","author":"A Al-abcha","year":"2022","unstructured":"Al-abcha A, Saleh Y, Elsayed M, Elshafie A, Herzallah K, Baloch ZQ, et al. Left atrial appendage closure versus oral anticoagulation in non-valvular atrial fibrillation: a systematic review and meta-analysis. Cardiovasc Revasc Med. 2022;36:18\u201324.","journal-title":"Cardiovasc Revasc Med"},{"issue":"10","key":"1138_CR75","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.121.057859","volume":"145","author":"R Galea","year":"2022","unstructured":"Galea R, De Marco F, Meneveau N, Aminian A, Anselme F, Gr\u00e4ni C, et al. Amulet or watchman device for percutaneous left atrial appendage closure: primary results of the SWISS-APERO randomized clinical trial. Circulation. 2022;145(10):724\u201338.","journal-title":"Circulation"},{"issue":"4","key":"1138_CR76","doi-asserted-by":"publisher","first-page":"334","DOI":"10.2174\/1573403X11666150805115822","volume":"11","author":"A Akinapelli","year":"2015","unstructured":"Akinapelli A, Bansal O, Chen JP, Pflugfelder A, Gordon N, Stein K, et al. Left atrial appendage closure\u2014the WATCHMAN device. Curr Cardiol Rev. 2015;11(4):334\u201340.","journal-title":"Curr Cardiol Rev"},{"key":"1138_CR77","unstructured":"John M, Mandrola M. Nov 03, 2023 this week in cardiology podcast\u2014Medscape\u2014Nov 03, 2023. Medscape. 2023."},{"key":"1138_CR78","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ahj.2022.05.001","volume":"250","author":"M Huijboom","year":"2022","unstructured":"Huijboom M, Maarse M, Aarnink E, van Dijk V, Swaans M, van der Heijden J, et al. COMPARE LAAO: rationale and design of the randomized controlled trial \u201cCOMPARing Effectiveness and safety of Left Atrial Appendage Occlusion to standard of care for atrial fibrillation patients at high stroke risk and ineligible to use oral anticoagulation therapy.\u201d Am Heart J. 2022;250:45\u201356.","journal-title":"Am Heart J"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01138-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01138-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01138-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T16:36:19Z","timestamp":1726763779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01138-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,14]]},"references-count":78,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["1138"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01138-5","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,14]]},"assertion":[{"value":"22 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research received no specific grant from any funding agency in the public or commercial or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"J.R.S. has no competing interests. T.A.C.d.V. reports nonfinancial support from Daiichi Sankyo and personal fees from Bristol-Myers-Squibb, both outside the submitted work. He also reports that he is a member of the adjudication committee of the LIMIT & DANCE trails, which are sponsored by the Population Health Research Institute. M.E.W.H. received consultancy and\/or speaker fees from Bayer Netherlands, Daiichi Sankyo, Boehringer Ingelheim, and BMS-Pfizer. Received an unrestricted research grant from the Dutch Federation of Anticoagulation Clinics. R.P. has no competing interests. J.R.d.G. received research grants (through institution) from Atricure Inc, Bayer, Boston, Scientific, Daiichi Sankyo, Johnson&Johnson, Medtronic. Received honoraria\/speaker\/consultancy fees from AtriaN Medical, Atricure Inc, Bayer, Berlin Chemie, Daiichi Sankyo, Menarini, Medtronic, Novartis, Servier. R.W.M.M. Jansen received honoraria for speaker fees from Bayer Netherlands, Daiichi Sankyo, Boehringer Ingelheim, and BMS-Pfizer.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"J.S., T.d.V., M.H., R.P., J.d.G., and R.J. were involved in drafting and revising the manuscript for intellectual content. All authors gave final approval for this manuscript to be published.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author\u2019s contributions"}},{"value":"Data sharing not applicable to this article as no datasets were generated for this review article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}